Scientific Advisory Board
ImaBiotech has established a scientific board composed of experts with a unique know-how in the mass spectrometry domain.
Prof. Ron HEEREN,
Professor & Director, M4I, Maastricht UMC, NE
After obtaining a Ph.D. in technical physics from the University of Amsterdam on plasma-surface interactions and two years of post-doctoral work on FTICR mass spectrometry, Prof. Heeren joined the MOLART research team at the FOM-Institute for Atomic and Molecular Physics as a project leader, heading the instrumental developments for paint cross-section analysis in early 1995.
Four years later, he started a research group focusing on macromolecular ion physics with high resolution mass spectrometry and the development of MALDI Imaging Mass Spectrometry at AMOLF. The MALDI Imaging Mass Spectrometric facility at FOM-AMOLF under his supervision is carries out studies on neurodegenerative diseases, the molecular basis of cancer, as well as several drug metabolic projects including innovative nanoparticle based drug delivery systems. He was appointed professor at Utrecht University lecturing on the physical aspects of biomolecular mass spectrometry, and remains active in the Netherlands Proteomics Centre and the Virtual Laboratory for e-sciences. His academic research interests include the energetics of macromolecular systems, conformational studies of non-covalently bound protein complexes, virtual laboratory technology and the development and validation of new mass spectrometry based proteomic imaging techniques for the life sciences.
Dr. Walter KORFMACHER
Director of Bioanalysis, Genzyme, Sanofi Group, Waltham, USA
Dr. Korfmacher obtained a Ph.D. in Chemistry from the University of Illinois in Urbana before spending over 25 years in the industry, which includes work for the FDA, the National Center for Toxicological Research, the University of Tennessee (Adjunct Associate Professor), the University of Arkansas for Medical Sciences, as well as nearly two decades at Schering-Plough/Merck. A Distinguished Fellow and a highly-respected group leader, Dr. Korfmacher’s research interests include the application of mass spectrometry to bioanalysis, including metabolite identification and trace organic quantitative methodology as well as MALDI Imaging Mass Spectrometry. He is a leader in the development of strategies for drug metabolism participation in new drug discovery via new MS techniques.
Dr. Korfmacher is currently Director of Bioanalysis at Genzyme, a Sanofi company, and Associate Editor, pharmaceutical sciences, for the Journal of Mass Spectrometry. He has served as the chairperson of the North Jersey Mass Spectrometry Discussion Group, and has received several awards for his scientific achievements. He is a member of three editorial boards: Rapid Communications in Mass Spectrometry; Current Drug Metabolism; and Drug Metabolism Letters. He has also edited three books: “Using Mass Spectrometry for Drug Metabolism Studies” (CRC Press, 2005), “Using Mass Spectrometry for Drug Metabolism Studies—Second Edition” (CRC Press, 2009) and “Mass Spectrometry for Drug Discovery and Drug Development” (Wiley, 2013) and has written chapters in five additional books. He has over 150 publications in scientific literature and has made over 80 presentations at various scientific forums.
Dr. Markus STOECKLI
Head of MALDI Imaging Mass Spectrometry, Novartis, Basel, CH
Dr. Stoeckli obtained his Ph.D. in 1996 from the University of Berne on the subject of mass spectrometry instrument design. In 1998, after a year of postdoctoral research at the University of Texas in Houston, he joined the faculty of the Vanderbilt University as a research instructor in the field of biological mass spectrometry. In the year 2000, Dr. Stoeckli joined the Novartis Institute for BioMedical Research in Basel where he is heading a MALDI Imaging Mass Spectrometric group. He is one of the pioneers in the field of label-free molecular imaging by mass spectrometry and his current work focuses on biomedical applications of this novel technology. Dr. Stoeckli in known for his many presentations at various scientific forums, where he openly discusses the application of MALDI Imaging Mass Spectrometry to the current drug discovery process at Novartis.